Perspective Therapeutics, Inc. (NYSE:CATX) Receives $20.00 Consensus PT from Analysts

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been assigned an average rating of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $20.00.

A number of brokerages recently issued reports on CATX. Oppenheimer reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 18th. Bank of America began coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 target price on the stock. Lifesci Capital reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 target price on shares of Perspective Therapeutics in a research report on Friday, June 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 25th.

Insider Activity

In other news, Director Robert F. Williamson III bought 3,003 shares of Perspective Therapeutics stock in a transaction dated Wednesday, May 29th. The shares were bought at an average price of $13.30 per share, for a total transaction of $39,939.90. Following the purchase, the director now owns 36,879 shares of the company’s stock, valued at $490,490.70. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Perspective Therapeutics news, CFO Jonathan Robert Hunt purchased 2,500 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was acquired at an average cost of $14.00 per share, with a total value of $35,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 34,171 shares of the company’s stock, valued at approximately $478,394. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert F. Williamson III purchased 3,003 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was acquired at an average cost of $13.30 per share, with a total value of $39,939.90. Following the completion of the acquisition, the director now directly owns 36,879 shares of the company’s stock, valued at $490,490.70. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 30,814 shares of company stock worth $385,487. Corporate insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Rhumbline Advisers bought a new position in shares of Perspective Therapeutics in the second quarter valued at about $630,000. Bank of New York Mellon Corp raised its holdings in shares of Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after buying an additional 93,548 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at about $138,000. Janus Henderson Group PLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at about $15,511,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at about $6,069,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $12.29 on Friday. Perspective Therapeutics has a 12 month low of $2.05 and a 12 month high of $19.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.98 and a current ratio of 12.98. The company has a 50 day moving average price of $12.15.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. The firm had revenue of $0.33 million during the quarter. Sell-side analysts forecast that Perspective Therapeutics will post -1.02 EPS for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.